These disclosures are from 13Ds filed with the Securities and Exchange Commission. 13Ds are filed within 10 days of an entity’s attaining more than 5% in any class of a company’s securities. Subsequent changes in holdings or intentions must be reported in amended filings. This material is from March 30 through April 5, 2023. Source: VerityData
Activist Holdings
American Public Education (APEI)
325 Capital increased its position in the postsecondary-education-services firm to 1,170,834 shares, or a 6.1% interest. 325 Capital purchased 229,901
American Public Education
shares from March 23 through March 27 at prices ranging from $4.53 to $4.86 apiece.
325 Capital entered into a cooperation agreement with the company on March 20 that led to the appointment of 325 Capital managing partner Michael Braner to American Public’s board on March 28. As a result, 235 Capital received a grant of 2,405 restricted shares, which are included in the stated ownership figures.
Increases in Holdings
Tilly’s
(TLYS)
Fund 1 Investments raised its holdings in the retailer of casual apparel to 5,164,352 shares. Fund 1 did so through the purchase of 443,840 Tilly’s shares from March 28 to April 4 at prices ranging from $7.12 to $7.67 apiece. This followed Fund 1’s purchase of 242,117 Tilly’s shares at an average price of $7.47 from March 10—when Fund 1 switched to an active investor—through March 14. Through the first week of April, Fund 1 now holds 22.9% of Tilly’s stock.
Glatfelter
(GLT)
Carlson Capital increased its position in the specialty-materials manufacturer to 5,915,000 shares. Affiliates of Carlson Capital bought 500,000 Glatfelter shares on March 29 at a price of $3.09 per share. Carlson, on Jan. 20, used options to acquire 50,000 Glatfelter shares at a price of $2.50 each. Carlson now holds 13.2% of the manufacturer’s tradable stock.
Decreases in Holdings
Amylyx Pharmaceuticals
(AMLX)
Morningside Venture Investments reduced its position in the pharmaceutical company to 8,618,846 shares. Morningside Venture sold a total of 683,296 Amylyx shares from Feb. 22 through March 29 at per share prices ranging from $30.25 to $36.34. Morningside Ventures now holds 12.9% of Amylyx’s outstanding stock.
Viking Therapeutics
(VKTX)
Ligand Pharmaceuticals
(LGND) slashed its stake in the clinical-stage pharmaceutical firm to 3,616,077 shares, or a 4.6% interest. Ligand sold a total of 2,449,003 Viking Therapeutics shares on March 28 and March 29 at prices ranging from $13.50 to $16.30 each.
Ligand has been unloading Viking Therapeutics shares since February, when it sold 650,000 shares at prices ranging from $8.08 to $9.43 apiece. Ligand’s sales preceded Viking Therapeutics’ offering of nearly 19.83 million shares at a price of $14.50 per share that closed on April 3.
As Ligand is no longer a 5% shareholder, it no longer needs to disclose any further Viking Therapeutics stock sales.
Email: editors@barrons.com
Read the full article here
